Jan Jensen

Jan Jensen has a diverse work experience in the field of cell therapy and regenerative medicine. Jan served as the CEO/CSO at Trailhead Biosystems Inc., where they developed a novel method involving mathematical models and systems biology analyses to optimize cell culture parameters for cell therapy development. Prior to Trailhead Biosystems, Jan Jensen held the position of Diabetes Research Director at Cleveland Clinic, focusing on treating diabetes through cell replacement methodology. Jan also served as the Scientific Director at OH-Alive, a cell therapy process optimization platform, and as the Program Director for the Pancreatic Progenitor Project. Jan Jensen has held various teaching positions at the University of Colorado, where they specialized in developmental biology and stem cell biology. Jan has also worked as a scientist and a Ph.D. student at Novo Nordisk A/S.

Jan Jensen completed their secondary education at Holstebro Gymnasium from 1983 to 1986, where they studied Mathematics and Physics. Jan then pursued higher education at the University of Copenhagen, also known as Københavns Universitet, from 1988 to 1998. During this period, Jan obtained both a Master of Science (M.Sc) degree and a Ph.D. in Biochemistry.